1SAVGE D G,ANTMAN K H.Imatinib mesylate-a new oral targeted therapy[J].N EngL J Med,2002,34:683-693.
2Cancer Therapy Evaluation Progarm. Common toxicity criteria, version 2.0[M]. Bethesda Md: National Cancer Institue,1998.20.
3KANTARJIAN H M,CORTES J, O'BRIEN S,et al. Imatinib mesylate (ST1 571) therapy of philadelphia chromosome-positive chronic myeloid leukemia in early chronic phase (Ph+ CML Early CP)[J]. Blood,2001,98:137.
4KANTARJIAN H M,O'BRIEN,S CORTES J,et al.Treatment of accelerated phase of philadelphia chromosome positive chronic myeloid leukemia (Ph+CML AP)with imatinib mesylate (STI 571)[J]. Blood,2001,98:141.
5SAVAGE MAN K H.Imatinib mesylate-a new oral targeted therapy[J]. N EngL J Med,2002,34:683-693.
10Palandri F, Castagnetti F, Alimena G, et al. The long-term durability of cytogenetic responses in patients with accelerated phase chronic myeloid leukemia treated with imatinib 600 mg: the GIMEMA CML Working Party experience after a 7-year follow-up. Haematologica, 2009; 94(2) : 205 -212.
